Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Express Scripts
Healthtrust
Daiichi Sankyo
QuintilesIMS
Boehringer Ingelheim

Generated: July 23, 2019

DrugPatentWatch Database Preview

Patent: 10,143,723

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,143,723
Title:Methods of using OX40 ligand encoding polynucleotides
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
Inventor(s): Frederick; Joshua P. (Boston, MA), Bai; Ailin (Newton, MA)
Assignee: ModernaTX, Inc. (Cambridge, MA)
Application Number:15/996,140
Patent Claims:see list of patent claims

Details for Patent 10,143,723

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Emd Serono Inc BAVENCIO avelumab INJECTABLE;INTRAVENOUS 761078 001 2017-05-09 ➤ Sign Up ModernaTX, Inc. (Cambridge, MA) ➤ Sign Up RX search
Astrazeneca Uk Ltd IMFINZI durvalumab INJECTABLE;INJECTION 761069 001 2017-05-01 ➤ Sign Up ModernaTX, Inc. (Cambridge, MA) ➤ Sign Up RX search
Emd Serono Inc BAVENCIO avelumab INJECTABLE;INJECTION 761049 001 2017-04-25 ➤ Sign Up ModernaTX, Inc. (Cambridge, MA) ➤ Sign Up RX Orphan search
Genentech Inc TECENTRIQ atezolizumab INJECTABLE; INJECTION 761041 001 2016-10-18 ➤ Sign Up ModernaTX, Inc. (Cambridge, MA) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Harvard Business School
Colorcon
Argus Health
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.